Nyxoah (NYXH) Q1 2026 earnings review
U.S. Launch Accelerates, But Cash Burn and Margins Require Attention
Nyxoah's U.S. commercial playbook is working. Q1 worldwide net revenue surged to €6.4M (+482% YoY), driven by a 25% sequential jump in U.S. sales to €4.3M. Early leading indicators are flawless: the company achieved a 100% prior-authorization approval rate and added 34 new high-volume active accounts. However, the cost of this growth is severe. Operating cash burn hit €21.6M for the quarter, leaving the company with just €25.9M in cash. To make matters more complicated, gross margin reversed trajectory, dropping to 57% due to manufacturing yield issues. While net income appeared to improve, this was largely an optical illusion driven by a €5.7M fair value gain on convertible bonds. Nyxoah is executing brilliantly on the top line, but it is walking a financial tightrope pending incoming debt tranches.
🐂 Bull Case
Achieving a 100% approval rate on reviewed U.S. prior authorization submissions removes the biggest structural barrier to adoption. Medicare issuing new C-Codes effectively normalizes the reimbursement landscape against established competitors.
The company rapidly scaled to 91 active high-volume U.S. accounts and trained 62 new surgeons in Q1 alone (bringing the total to 207). At 241 patients submitted for prior authorization, the leading indicators suggest sustained revenue momentum.
🐻 Bear Case
With €25.9M in cash and a quarterly operating cash burn of €21.6M, the company has an uncomfortably short runway without external capital injections. They are highly dependent on the incoming €13.8M EIB tranche in Q2 to maintain operations.
Gross margin abruptly dropped to 57% from 64% last quarter. While management cited an 'addressed' yield issue, scaling hardware manufacturing while trying to expand a sales force introduces significant execution risk.
⚖️ Verdict: ⚪
Neutral. The commercial traction and market access achievements are undeniably bullish. However, the high cash burn, sudden gross margin compression, and reliance on incoming debt to fund the next few quarters demand a cautious approach.
Key Themes
U.S. Launch Momentum is Accelerating
U.S. net revenue grew 25% sequentially to €4.3M, proving that Nyxoah's initial Q4 commercial debut was not merely a channel-fill event. The company expanded its active high-volume accounts from 57 in Q4 to 91 in Q1, and trained an additional 62 surgeons. This expanding funnel (241 patients submitted for prior authorization) suggests the Q2 U.S. revenue guidance of +25-30% QoQ is highly credible.
Reimbursement Friction Successfully Eliminated
Reimbursement is often the graveyard for promising medical devices. Nyxoah has largely neutralized this risk. They secured a 100% prior-authorization approval rate on reviewed submissions with commercial payers. Furthermore, Medicare issued new C-Codes covering Genio, matching the facility and physician payment economics of the incumbent competitor. This ensures hospitals have no financial disincentive to use the Genio system.
Gross Margin Reverses Due to Yield Issues
After establishing a mid-60s margin profile in 2025 (64% in Q4), gross margin fell sharply to 57% in 26Q1. Management explicitly blamed a 'lower yield' on the manufacturing side, claiming it has been addressed. However, full-year guidance of 60-62% implies that margin pressure will persist. True margin expansion is unlikely until the next-generation Genio 2.2 activation chip launches, currently slated for 2027.
Liquidity Position Reaching Critical Levels
Cash, cash equivalents, and financial assets halved in a single quarter, dropping from €48.0M at the end of 2025 to €25.9M by March 31, 2026. With SG&A jumping to €15.4M to fund the U.S. launch, operating cash flow for the quarter was deeply negative (-€21.6M). The company expects to draw €13.8M from the EIB loan in Q2 to bridge the gap, but the short runway leaves zero room for commercial missteps or unforeseen legal expenses.
Ongoing Intellectual Property Litigation
The interim report highlights ongoing patent litigation. Inspire Medical sued Nyxoah in May 2025, and Nyxoah filed a countersuit in September 2025. While no provision has been recorded yet, legal fees contributed to the 24% YoY increase in SG&A expenses. Prolonged litigation against a well-capitalized incumbent serves as an ongoing drag on OpEx and management focus.
Other KPIs
Stable YoY (vs €20.6M in 25Q1). While revenue grew by €5.3M YoY, SG&A expenses expanded by €3.0M to support the U.S. commercial build-out, completely offsetting the gross profit gains at the operating line. The company is actively sacrificing near-term profitability to capture U.S. market share.
Net income (-€15.9M) looks artificially better than operating income (-€20.5M) due to a massive €5.7M gain on the change in fair value of the convertible bond and synthetic warrant liabilities. Investors should look strictly at Operating Loss and Cash Flow to gauge the core business economics.
Guidance
Accelerating absolute dollar growth. Building on Q1's €4.3M, the midpoint implies Q2 U.S. revenue of roughly €5.48M. This indicates strong confidence in the conversion of the 241 patients currently sitting in the prior-authorization funnel.
Accelerating massively. This compares to roughly €10M in FY25, representing nearly 280% YoY growth at the midpoint. This assumes sequential U.S. growth continues compounding throughout the back half of the year.
Decelerating/Stable. This implies an improvement from the 57% realized in Q1, but structurally lower than the 64% peak achieved in Q4 2025. It underscores that manufacturing scale and yield optimization will take time.
The guide implies an average cash OpEx of roughly €22.2M per quarter. With €25.9M in cash on the balance sheet, it mathematically confirms why drawing down the EIB and convertible bond debt tranches is an absolute necessity for survival through 2026.
Key Questions
Manufacturing Yield Issue Details
Gross margin dropped 700 basis points sequentially due to a 'lower yield'. What exactly failed in the manufacturing process, and what structural changes were implemented to guarantee this has been permanently addressed?
Convertible Bond Tranche 2 Timing
With €25.9M in cash and a €21M+ quarterly operating burn rate, the expected €13.8M EIB draw provides a bridge but not a long-term solution. Under what specific conditions and timeline do you plan to trigger the second €22.5M tranche of the convertible bond?
ACCCESS Study & Label Expansion Timeline
How does the current U.S. launch execution influence the timeline for submitting the PMA supplement based on the ACCCESS study data to secure a full on-label indication for Complete Concentric Collapse (CCC) patients?